Orchard Therapeutics Received FDA Fast Track Designation For OTL-203, An Investigational Hematopoietic Stem Cell Gene Therapy Being Developed For The Potential Treatment Of The Hurler Subtype Of Mucopolysaccharidosis Type I

11/30/23 7:04:05 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ORTX alert in real time by email

Get the next $ORTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ORTX

Date	Price Target	Rating	Analyst
12/29/2021	$12.00 → $9.00	Overweight	Cantor Fitzgerald
11/16/2021		Neutral → Underweight	JP Morgan
11/5/2021	$15.00 → $13.00	Outperform	Oppenheimer
8/18/2021		Overweight → Neutral	JP Morgan

More analyst ratings

$ORTX
Financials

Live finance-specific insights

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
TOKYO and LONDON and BOSTON, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc ((Orchard Therapeutics, NASDAQ:ORTX), a global gene therapy leader, today announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics. The acquisition of all outstanding shares of Orchard Therapeutics by way of a Scheme of Arrangement procedure under the UK Companies Act 2006 was completed on January 24, 2024, and Orchard Therapeutics has become a wholly-owned subsidiary of Kyowa Kirin.
1/24/24 5:00:00 AM ET
$ORTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Kyowa Kirin to Acquire Orchard Therapeutics
-Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin's portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a total maximum equity value of approximately $477.6 million--Kyowa Kirin to host investor conference call on Oct 5 at 18:30 p.m. JST- TOKYO and LONDON and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Ky
10/5/23 3:35:06 AM ET
$ORTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
Reported $6.6M in Q2'23 Libmeldy net sales, representing the highest quarter to date $34.0M of additional capital from second closing of strategic financing extends runway to mid-2025 Four MLD patients identified from ~150,000 newborns screened in prospective studies suggests significantly higher incidence than previously estimated in the medical literature Six presentations at ASGCT demonstrate the ability of HSC gene therapy to address neurometabolic and CNS disorders, as well as larger indications Company to host conference call and live webcast today at 8:00 a.m. EDT BOSTON and LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene th
8/3/23 7:00:09 AM ET
$ORTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first quarter of 2024 Biologics License Application for OTL-200 in MLD accepted by U.S. FDA under Priority Review; PDUFA date set for March 18, 2024 Ten prospective newborn screening studies are active globally with approximately 200,000 babies screened Eight presentations at ESGCT highlighted the differentiated profile and potential broad applicability of the company's HSC gene therapy platform BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene the
11/13/23 7:00:00 AM ET
$ORTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed biotechsBritish Patient Capital invests £10 million in a Series B extension bringing total raised in this round to £85.5 million Oxford, United Kingdom – 15 May 2023 – OMass Therapeutics (‘OMass', or ‘the Company'), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the appointment of Jim Geraghty as chairman of its board of directors and an additional investment of £10 million from new inve
5/15/23 2:00:00 AM ET
$FULC
$ORTX
$PIRS
$VYGR
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company's strategic focus on innovation in the areas of discovery, clinical development and manufacturing BOSTON and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the appointment of two gene therapy and industry experts, Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., to serve as chief scientific officer and chief technical officer, respectively
9/9/21 7:00:00 AM ET
$ORTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 7-11, 2024, in Baltimore. Featured data include several accepted abstracts and an Oral Presidential Symposium supporting the safety and efficacy of atidarsagene autotemcel (formerly OTL-200 which was recently approved as Lenmeldy™ in the
5/7/24 7:00:17 AM ET
$ORTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, has been named to the inaugural 2024 TIME100 Health, an annual list recognizing the impact, innovation, and achievement of the world's most influential individuals in health this year. The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/. "I am incredibly humbled, privileged, and immensely proud to b
5/3/24 7:00:38 AM ET
$ORTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout the treatment process Lenmeldy wholesale acquisition cost of $4.25 million for one-time treatment reflects its clinical, economic and societal value Innovative outcomes- and value-based agreements are being offered to both private and government insurers to ensure broad, expedient and sustainable reimbursed access TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the de
3/20/24 7:00:07 AM ET
$ORTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Orchard Therapeutics Received FDA Fast Track Designation For OTL-203, An Investigational Hematopoietic Stem Cell Gene Therapy Being Developed For The Potential Treatment Of The Hurler Subtype Of Mucopolysaccharidosis Type I

Chat with this insight

Recent Analyst Ratings for $ORTX

$ORTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald resumed coverage on Orchard Therapeutics with a new price target

Orchard Therapeutics downgraded by JP Morgan

Oppenheimer reiterated coverage on Orchard Therapeutics with a new price target

$ORTX Financials

Live finance-specific insights

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

Kyowa Kirin to Acquire Orchard Therapeutics

Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA

$ORTX Market Insights

Live Market Insights

Orchard Therapeutics Reached An Agreement With The Beneluxa Initiative On Pharmaceutical Policy (Beneluxa) Enabling Reimbursed Access To Libmeldy= (atidarsagene autotemcel) Approved For The Treatment Of Early-onset Metachromatic Leukodystrophy (MLD)

Kyowa Kirin Completes Acquisition Of Orchard Therapeutics

Orchard Therapeutics Wins Swissmedic Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy (MLD)

$ORTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$ORTX Leadership Updates

Live Leadership Updates

SEC Form 4 filed by Secor Alicia

Geraghty James A returned 44,391 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)

Thomas Frank E returned 92,081 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)

Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments

$ORTX SEC Filings

SEC Form 15-12G filed by Orchard Therapeutics plc

SEC Form EFFECT filed by Orchard Therapeutics plc

SEC Form EFFECT filed by Orchard Therapeutics plc

$ORTX Press Releases

Fastest customizable press release news feed in the world

Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

$ORTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Orchard Therapeutics plc

SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)

SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)

Recent Analyst Ratings for
$ORTX

$ORTX
Analyst Ratings

$ORTX
Financials

$ORTX
Market Insights

$ORTX
Insider Trading

$ORTX
Leadership Updates

$ORTX
SEC Filings

$ORTX
Press Releases

$ORTX
Large Ownership Changes